PerkinElmer Acquires Spectral Genomics
News May 02, 2006
PerkinElmer, Inc. has announced the acquisition of the assets of Spectral Genomics, Inc. Spectral Genomics' array products and analysis software help pharmaceutical, biotechnology, cytogenetic and clinical researchers identify chromosomal abnormalities related to the study of cancer and pre- and post-natal genetic disorders.
The company's proprietary Array CGH (Comparative Genome Hybridization) technology is designed to provide a high-resolution global view of the human genome, enabling researchers to identify the exact location of any chromosomal deletions and amplifications that can cause an increased risk of genetic disease.
"Spectral Genomics' innovative technologies are highly complementary to our current molecular medicine and genetic screening offerings," said Robert F. Friel, president, PerkinElmer Life and Analytical Sciences.
"By enabling rapid surveys of the whole genome at high resolution, scientists can produce abundant, highly reproducible data in a fraction of the time required with standard methods, driving higher productivity in the lab."
Array-based karyotyping is widely expected to replace Florescent In-Situ Hybridization (FISH), G-banding microscopic analysis and other conventional forms of karyotyping in the cytogenetic market, which was valued at approximately $1.4 billion in 2004.
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells varies from cell to cell, caused by somatic changes. But much remains unknown, including when these changes arise, their size and locations, and whether they are random or regulated. Now, researchers have developed new techniques allowing the detection of CNVs smaller than one million base pairs.